ABSTRACT
The field of radionuclide therapy (RNT) for prostate cancer (PC) is growing rapidly, with recent Food and Drug Administration approval of the first 177Lu-PSMA ligand. We aimed to develop the first patient-reported outcome (PRO) measure for PC patients receiving RNT. Methods: We identified relevant symptoms and toxicities by reviewing published trials and interviews with PC patients receiving RNT (n = 29), caregivers (n = 14), and clinicians (n = 11). Second, we selected items for measure inclusion. Third, we refined the item list with input from experts in RNTs and PROs. Fourth, we finalized the Functional Assessment of Cancer Therapy-Radionuclide Therapy (FACT-RNT) with patient input. Results: This multistep process yielded a brief 15-item measure deemed by key stakeholders to be relevant and useful in the context of RNT for PC. Conclusion: The FACT-RNT is a new standardized tool to monitor relevant symptoms and toxicities among PC patients in RNT trials and real-world settings.
Subject(s)
Prostatic Neoplasms , Male , Humans , Prostatic Neoplasms/radiotherapy , Prostatic Neoplasms/drug therapy , Radioisotopes/therapeutic use , Patient Reported Outcome MeasuresABSTRACT
The purpose of this study was to evaluate 18F-FLT PET/CT as an early prognostic imaging biomarker of long-term overall survival and disease-specific survival (DSS) in soft-tissue sarcoma (STS) patients treated with neoadjuvant therapy (NAT) and surgical resection. Methods: This was a 10-y follow-up of a previous single-center, single-arm prospective clinical trial. Patients underwent 18F-FLT PET/CT before treatment (PET1) and after NAT (PET2). Posttreatment pathology specimens were assessed for tumor necrosis or fibrosis and for Ki-67 and thymidine kinase 1 expression. Maximally selected cutoffs for PET and histopathologic factors were applied. Survival was calculated from the date of subject consent to the date of death or last follow-up. Results: The study population consisted of 26 patients who underwent PET1; 16 of the 26 with primary STS underwent PET2. Thirteen deaths occurred during a median follow-up of 104 mo. In the overall cohort, overall survival was longer in patients with a low than a high PET1 tumor SUVmax (dichotomized by an SUVmax of ≥8.5 vs. <8.5: not yet reached vs. 49.7 mo; P = 0.0064). DSS showed a trend toward significance (P = 0.096). In a subanalysis of primary STS, DSS was significantly longer in patients with a low PET1 tumor SUVmax (dichotomized by an SUVmax of ≥8 vs. <8; P = 0.034). There were no significant 18F-FLT PET response thresholds corresponding to DSS or overall survival after NAT at PET2. Conclusion:18F-FLT PET may serve as a prognostic baseline imaging biomarker for DSS in patients with primary STS.
Subject(s)
Positron Emission Tomography Computed Tomography , Sarcoma , Biomarkers , Fluorodeoxyglucose F18 , Humans , Positron Emission Tomography Computed Tomography/methods , Positron-Emission Tomography , Prognosis , Prospective Studies , Radiopharmaceuticals/therapeutic use , Sarcoma/diagnostic imaging , Sarcoma/therapyABSTRACT
ABSTRACT: A 3-year-old, previously healthy girl started having clusters of seizures, not responsive to multiple antiepileptic medications. High-dose prednisone and intravenous immunoglobulin could partially control the seizures. Lumbar puncture and CT were normal. An MRI showed right hemispheric injury and atrophy compatible with clinical suspicion of Rasmussen encephalitis. Neurological 18F-FDG PET/CT demonstrated asymmetric hypermetabolic activity in the right frontal and parietal lobes compatible with active inflammation. The patient underwent a right functional hemispherectomy, which confirmed clinical suspicion of Rasmussen encephalitis. During the follow-up, the patient has continued to take phenobarbital and levetiracetam (Keppra), with no recurrence of seizures.